Olema Pharmaceuticals (OLMA) Competitors $8.35 +0.18 (+2.20%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OLMA vs. ANIP, RXRX, TVTX, BEAM, TARS, IRON, DNLI, ARQT, ADPT, and MESOShould you be buying Olema Pharmaceuticals stock or one of its competitors? The main competitors of Olema Pharmaceuticals include ANI Pharmaceuticals (ANIP), Recursion Pharmaceuticals (RXRX), Travere Therapeutics (TVTX), Beam Therapeutics (BEAM), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Denali Therapeutics (DNLI), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), and Mesoblast (MESO). These companies are all part of the "pharmaceutical products" industry. Olema Pharmaceuticals vs. Its Competitors ANI Pharmaceuticals Recursion Pharmaceuticals Travere Therapeutics Beam Therapeutics Tarsus Pharmaceuticals Disc Medicine Denali Therapeutics Arcutis Biotherapeutics Adaptive Biotechnologies Mesoblast Olema Pharmaceuticals (NASDAQ:OLMA) and ANI Pharmaceuticals (NASDAQ:ANIP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment. Is OLMA or ANIP more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.37%. ANI Pharmaceuticals' return on equity of 25.03% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -42.58% -38.65% ANI Pharmaceuticals -1.37%25.03%8.00% Which has stronger earnings & valuation, OLMA or ANIP? ANI Pharmaceuticals has higher revenue and earnings than Olema Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$129.47M-$1.98-4.22ANI Pharmaceuticals$614.38M3.39-$18.52M-$0.77-124.56 Which has more volatility & risk, OLMA or ANIP? Olema Pharmaceuticals has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Do insiders & institutionals hold more shares of OLMA or ANIP? 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are owned by institutional investors. 16.4% of Olema Pharmaceuticals shares are owned by company insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer OLMA or ANIP? In the previous week, ANI Pharmaceuticals had 5 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 13 mentions for ANI Pharmaceuticals and 8 mentions for Olema Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 0.95 beat Olema Pharmaceuticals' score of 0.12 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ANI Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend OLMA or ANIP? Olema Pharmaceuticals currently has a consensus target price of $24.00, suggesting a potential upside of 187.43%. ANI Pharmaceuticals has a consensus target price of $93.00, suggesting a potential downside of 3.04%. Given Olema Pharmaceuticals' higher probable upside, equities research analysts plainly believe Olema Pharmaceuticals is more favorable than ANI Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.11 SummaryANI Pharmaceuticals beats Olema Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OLMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OLMA vs. The Competition Export to ExcelMetricOlema PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.40M$3.17B$5.81B$10.48BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-4.2221.28350.7626.80Price / SalesN/A405.78520.14162.62Price / CashN/A44.8326.0131.15Price / Book1.179.8215.486.48Net Income-$129.47M-$53.02M$3.30B$271.51M7 Day Performance4.38%3.05%200.54%3.24%1 Month Performance44.97%4.94%184.07%7.52%1 Year Performance-38.78%12.71%325.10%29.17% Olema Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OLMAOlema Pharmaceuticals2.7548 of 5 stars$8.35+2.2%$24.00+187.4%-40.1%$573.40MN/A-4.2270ANIPANI Pharmaceuticals4.0197 of 5 stars$98.81+1.1%$88.25-10.7%+62.2%$2.12B$614.38M-128.32600RXRXRecursion Pharmaceuticals2.3443 of 5 stars$4.77-1.2%$7.25+52.0%-27.8%$2.10B$58.84M-2.68400Positive NewsGap UpTVTXTravere Therapeutics2.7171 of 5 stars$23.01-2.0%$34.20+48.6%+63.4%$2.09B$233.18M-11.28460Analyst ForecastBEAMBeam Therapeutics2.9956 of 5 stars$21.28+3.3%$46.40+118.0%-5.2%$2.08B$63.52M-4.73510TARSTarsus Pharmaceuticals2.3307 of 5 stars$49.59+0.5%$66.67+34.4%+59.4%$2.08B$182.95M-21.2850IRONDisc Medicine3.0885 of 5 stars$59.90+0.1%$98.30+64.1%+26.4%$2.08BN/A-13.4030Positive NewsDNLIDenali Therapeutics4.1789 of 5 stars$13.16-7.3%$33.50+154.6%-58.8%$2.07B$330.53M-4.70430ARQTArcutis Biotherapeutics2.1734 of 5 stars$16.93-2.1%$19.80+17.0%+71.2%$2.07B$196.54M-22.57150Positive NewsADPTAdaptive Biotechnologies3.413 of 5 stars$13.08+3.7%$12.38-5.4%+187.3%$1.92B$205.22M-15.95790Positive NewsMESOMesoblast1.0695 of 5 stars$15.46+4.3%$18.00+16.4%+148.3%$1.90B$17.20M0.0080Positive NewsGap Up Related Companies and Tools Related Companies ANIP Alternatives RXRX Alternatives TVTX Alternatives BEAM Alternatives TARS Alternatives IRON Alternatives DNLI Alternatives ARQT Alternatives ADPT Alternatives MESO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OLMA) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
